Editorial
1953 Classification and diagnostic criteria in Sjögren’s syndrome: a long-standing and still open controversy
C Vitali, N Del Papa

Criteria
1955 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

Recommendations
1965 European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative

Clinical and epidemiological research
1980 Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients

1986 Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
P Emery, J Vencovsky, A Sywesrzak, P Leszczyński, W Poczynski, B Stasiuk, J Hilt, Z Mosterova, S Y Cheong, J Ghil

1992 Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece

2001 Sirukumab for rheumatoid arthritis: the phase III SIIRROUND-D study
Takachi, C Thorn, G Karppouzas, S Sheng, W Xu, R Rao, F Kei, B Hsu, P P Taked

2009 Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016
A M Tettone, I B Lewandowski, J Hu, A Dasgupta, M M Ward

2017 Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis
A Mamed, A Holmøy, T Jernberg, S Wällberg-Jonsson, J Aakj

2025 Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.
ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of the authors.
Copyright © 2017 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved. No part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying or recording, or otherwise without prior permission.

Volume 76 Issue 12 | ARD December 2017

Contents

Clinical and epidemiological research

This article has been chosen by the Editor to be of special interest and is freely available online.
This article has been made freely available online under the BMJ Journals Open Access scheme.

http://authors.bmj.com/open-access/

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
http://publicationethics.org/

Copyright BMJ Publishing Group Ltd. This document is for personal, non-commercial use only. Content is not to be distributed or shared.
Basic and translational research

2075 Chemotaxis of V62 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis

2085 A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever

2095 B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis
A Cortini, U Ellingham, T H Malik, D S Conningham-Graham, M Botto, T J Vyse

2105 Identification of a transitional fibroblast function in very early rheumatoid arthritis
A Filer, L S C Wood, S Kemble, C S Davies, H Munir, R Rogers, K Reza, C D Buckley, G B Nash, H M McGettick

Correction

2103 Erratum: Dietary intake of fibre and risk of knee osteoarthritis in two US prospective cohorts

Electronic pages

Correspondence
e49 Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis
I Pirilä, T Sokka, M J Kauppila, V M Rantalaaho, E Mervaala, K Paalakka

e50 Response to: 'The time has come to revisit EULAR recommendations for rheumatoid arthritis' by Pirilä et al
J S Smolen, R B M Landewé, D van der Heijde

e51 HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study
J Blutt, S-A Owen, J Massey, A Alfiviec, M Pirnghomeed, D Platt, S M M Versstphen, A Barton, on behalf of The Pneumonitis Study Consortium

e52 Response to: 'HLA-A* 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome wide association study' by Blutt et al
H Furukawa, S Oka, K Shimada, N Tsuchiya, S Tobma, on behalf of the Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) Study Consortium

e53 EULAR recommendations underplay importance of severe anxiety and depression in fibromyalgia treatment
C Mericica, A A Borg

e54 EULAR recommendations for management of fibromyalgia